Europe and Israel Expand Access to Moderna's COVID-19 Vaccine
Massachusetts-based Moderna, Inc. and Medison Pharma announced a new agreement to commercialize the experimental Moderna COVID-19 Vaccine across Central Eastern Europe and Israel.
"We are excited to partner with Moderna in 20 markets, covering over 175 million lives across the entire Central Eastern Europe region and in Israel,” commented Meir Jakobsohn, Founder and CEO of Switzerland-based Medison Pharma.
“Moderna’s breakthrough vaccine and Medison’s international commercialization platform for highly innovative treatments makes our partnership a natural fit.”
This agreement covers the following countries: Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia and Herzegovina, Kosovo, North Macedonia, Montenegro, and Israel.
The U.S. FDA issued Authorization for the Moderna vaccine in December 2020 but has not Authorized it as of June 7, 2021.